Latest Breaking News On - Return from rock bottom secondary offering - Page 1 : comparemela.com

Inozyme Pharma (NASDAQ:INZY) has been experiencing high levels of insider accumulation, with five net insiders acquiring shares over the last 90 days.

Zhang huiEun yangKurt gunterDarkostojanovic pixabaySuji jeongVenture partners fundInozyme pharma insiders bankHc wainwright co analyst edward whiteReturn from rock bottom secondary offeringManager profileZhang hui of chinaSouthern assetActivist investing caseSan francisco basedLongitude capitalKurt gunter chief medical